Clinical Trials · NCT04504396
Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- PegBio Co., Ltd.
- Enrollment
- 620
- Start date
- Jun 2020
- Locations
- 1 site, China
- Primary endpoint
- Change in HbA1c